Current stock price

Investor Relations

GCANRx is a publicly traded biotechnology company led by an experienced team of executives and scientists. The company is focused on the the development and commercialization of innovative Cannabinoid delivery systems.

Aug 11, 2020

Greater Cannabis Partners with Leading Beauty Brand, Cinema Secrets

Jun 12, 2020

Greater Cannabis Launches CBD Oral Patch Product With European Partner Symtomax

Jun 08, 2020

The Greater Cannabis Company Completes International Shipment of 125,000 Oral CBD Patches

Corporate Presentation

See our latest corporate presentation.

Stock Information

See our current stock performance.

Aitan Zacharin

Aitan Zacharin

CEO, Director

Mark Radom

Mark Radom

VP, General Counsel

David Tavor

David Tavor

Director, Board of Directors

Hock S. Tan

Hock S. Tan, PhD

Chairman, Scientific Advisory Board

More about our management

SEC Filings

Aug 13, 2020

Form NT 10-Q

Jul 22, 2020

Form DEF 14C

Jul 17, 2020



What is the ticker symbol for GCANRx?

Shares of GCANRx are traded on the OTC Markets under the ticker symbol GCAN.

Where is GCANRx’s corporate headquarters?

GCANRx is based out of Baltimore, MD.

When does GCANRx’s fiscal year end?

December 31.

Who is GCANRx’s transfer agent?

Pacific Stock Transfer. 6725 Via Austi Pkwy, Suite 300 Las Vegas, NV 89119. (800) 785-7782.

Who is GCANRx’s auditor?

Michael T. Studer CPA P.C. 111 West Sunrise Highway, Second Floor East Freeport, NY 11520, United State

What is GCANRx's CUSIP number?


What is GCANRx's CIK Number?


What is GCANRx's SIC and Classification?

2834; Pharmaceutical Preparations

What is GCANRx's O/S and Float?

As of October 26, 2018 the outstanding shares are 30,846,492 and the float is approximately 13,426,759

Sign up for email alerts

Stay up to date on the latest news.